First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
17h
Co-Diagnostics Announces First Full Vector Smart® Laboratory Installation for Native American Tribe
Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that ...
(Nasdaq: CNSY) (“Cerenome” or the “Company ”), today announced the commercial launch of two new cerebrospinal fluid (CSF)-based molecular profiling tests, available to health care professionals in the ...
ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the "Company"), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical ...
Title: "High-Throughput Enteric Testing: Advancing Speed, Scale, and Stewardship" Inside Molecular: Conversations Across BD Molecular Diagnostics is a podcast series exploring the BD Molecular ...
New automation platform brings open, AI-assisted automation to molecular microbiology and NGS workflows, with configurations from €50,000 to €90,000 WOIPPY, FRANCE, October 5, 2026 /EINPresswire.com/ ...
Point-of-care molecular diagnostics are gaining traction, reducing costs, improving outcomes and combating antimicrobial resistance, with potential to replace frontline testing protocols.Dublin, Sept.
NDTV Profit on MSN
Molbio Diagnostics shares in focus as Motilal Oswal initiates coverage; check target price
Motilal Oswal believes Molbio's successful diversification beyond TB, stronger international adoption and improving cash conversion could support a re-rating, while dependence on government orders and ...
Transaction value based on SEC Form 4 weighted average sale price ($100.00); post-transaction value based on August 25, 2026 market close ($100.08). BillionToOne develops advanced molecular diagnostic ...
Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique (INSP), which is supporting the DRC's Ministry of Health-led Ebola response. Roche will ...
Denials of clinical laboratory, molecular diagnostic, and genomics claims rose to 11.2% in 2025 from 8.0% the year before, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results